FR2969153B1 - Procede de purification de proteine amyloide p et utilisation de la proteine ainsi purifiee - Google Patents

Procede de purification de proteine amyloide p et utilisation de la proteine ainsi purifiee

Info

Publication number
FR2969153B1
FR2969153B1 FR1060769A FR1060769A FR2969153B1 FR 2969153 B1 FR2969153 B1 FR 2969153B1 FR 1060769 A FR1060769 A FR 1060769A FR 1060769 A FR1060769 A FR 1060769A FR 2969153 B1 FR2969153 B1 FR 2969153B1
Authority
FR
France
Prior art keywords
protein
amyloid
purified
purification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1060769A
Other languages
English (en)
Other versions
FR2969153A1 (fr
Inventor
Catherine Chenou
Jean Francois Prost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Priority to FR1060769A priority Critical patent/FR2969153B1/fr
Priority to PCT/EP2011/073127 priority patent/WO2012080500A1/fr
Priority to EP11796719.0A priority patent/EP2651970A1/fr
Priority to US13/993,292 priority patent/US20130259801A1/en
Publication of FR2969153A1 publication Critical patent/FR2969153A1/fr
Application granted granted Critical
Publication of FR2969153B1 publication Critical patent/FR2969153B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
FR1060769A 2010-12-17 2010-12-17 Procede de purification de proteine amyloide p et utilisation de la proteine ainsi purifiee Expired - Fee Related FR2969153B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1060769A FR2969153B1 (fr) 2010-12-17 2010-12-17 Procede de purification de proteine amyloide p et utilisation de la proteine ainsi purifiee
PCT/EP2011/073127 WO2012080500A1 (fr) 2010-12-17 2011-12-16 Proteine amyloide p serique
EP11796719.0A EP2651970A1 (fr) 2010-12-17 2011-12-16 Proteine amyloide p serique
US13/993,292 US20130259801A1 (en) 2010-12-17 2011-12-16 Serum amyloid p protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1060769A FR2969153B1 (fr) 2010-12-17 2010-12-17 Procede de purification de proteine amyloide p et utilisation de la proteine ainsi purifiee

Publications (2)

Publication Number Publication Date
FR2969153A1 FR2969153A1 (fr) 2012-06-22
FR2969153B1 true FR2969153B1 (fr) 2014-10-17

Family

ID=45349217

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1060769A Expired - Fee Related FR2969153B1 (fr) 2010-12-17 2010-12-17 Procede de purification de proteine amyloide p et utilisation de la proteine ainsi purifiee

Country Status (4)

Country Link
US (1) US20130259801A1 (fr)
EP (1) EP2651970A1 (fr)
FR (1) FR2969153B1 (fr)
WO (1) WO2012080500A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7442505B2 (ja) 2018-08-21 2024-03-04 コーニンクレッカ フィリップス エヌ ヴェ アミロイドスクリーニング方法及び装置
WO2022211014A1 (fr) * 2021-03-31 2022-10-06 株式会社カネカ Procédé de mesure de protéine d'agrégation, procédé de visualisation d'agrégation et kit destiné à être utilisé dans lesdits procédés

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516081D0 (en) * 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
US5216127A (en) * 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
GB9323826D0 (en) 1993-11-19 1994-01-05 Royal Postgrad Med School Diagnosis of alzheimer's disease
EP2730659A3 (fr) * 2007-12-28 2016-01-13 Prothena Biosciences Limited Traitement et Prophylaxie de L'amylose
AU2008358292B2 (en) * 2008-06-27 2015-05-07 Pentraxin Therapeutics Limited Use
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application

Also Published As

Publication number Publication date
WO2012080500A1 (fr) 2012-06-21
US20130259801A1 (en) 2013-10-03
FR2969153A1 (fr) 2012-06-22
EP2651970A1 (fr) 2013-10-23

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
BR112013008738A2 (pt) processos para purificação de proteínas
SMT201500142B (it) Procedimento per la purificazione di proteine
DK2558446T3 (da) Nye forbindelser til behandling af sygdomme associerede med amyloid- eller amyloidlignende proteiner
DK3251678T3 (da) Benzoxaborolderivater til behandling af bakterieinfektioner
SG11201406408RA (en) Purification of biological molecules
DK2598514T3 (da) Proteinoprensning
EE01079U1 (et) Territooriumi ja selle perimeetri j„lgimise ssteem
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
BR112013024521A2 (pt) métodos de purificação de proteínas
DK2861214T3 (da) Tilpassede liposomer til behandling af bakterieinfektioner
BR112014015551A2 (pt) método para tratar lama e método para desidratação de lama
DK3133157T3 (da) Fremgangsmåde til oprensning af vitamin k-afhængige proteiner
ES2547827T8 (es) Procedimiento para la purificación de la micafungina
IT1402749B1 (it) Composizioni per il trattamento di ulcere periferiche di varia origine
EE201300004A (et) Kombineeritud ravimkoostis sdame-veresoonkonnaga seotud haiguste v?i seisundite raviks
FR2966150B1 (fr) Procede de preparation de la 2-hydroxybutyrolactone
EP3045180A4 (fr) Combinaisons de protéines agrégantes et de chaperons moléculaires pour le traitement de protéinopathies ou de maladies confromationnelles
FR3008425B1 (fr) Procede de purification du niobium et/ou du tantale
FR2969153B1 (fr) Procede de purification de proteine amyloide p et utilisation de la proteine ainsi purifiee
FR2957496B1 (fr) Article chaussant et procede de ressemelage dudit article
FR2998894B1 (fr) Procede de fractionnement d'algues et utilisation des molecules obtenues
FR2963551B1 (fr) Ceinture de soutien du torse ou orthese de soutien du torse
FR2999175B1 (fr) Procede d'isolement de diamandoides
DK2656075T3 (da) Fremgangsmåde til optimering af behandlingen af patienter med biologiske lægemidler

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20150831